Research Analysts Set Expectations for ACHV FY2028 Earnings

Key Points

• HC Wainwright lowered its FY2028 EPS forecast for Achieve Life Sciences to $0.23 from $0.24, while maintaining a Buy rating and $12 price target. It projects EPS of $0.97 in FY2029 and $1.47 in FY2030.
• Achieve reported a quarterly loss of $0.80 per share, substantially below the consensus estimate of a $0.16 loss. Analysts nevertheless maintain an overall Buy consensus, with an average price target of $16.
• Shares opened at $6.77 and were up 1.5%, with the stock trading near its 52-week high and institutional investors owning 33.52% of outstanding shares.

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Stock analysts at HC Wainwright decreased their FY2028 earnings per share (EPS) estimates for shares of Achieve Life Sciences in a research note issued on Tuesday, August 11th. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will post earnings per share of $0.23 for the year, down from their prior forecast of $0.24. HC Wainwright currently has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Achieve Life Sciences' current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Achieve Life Sciences' FY2029 earnings at $0.97 EPS and FY2030 earnings at $1.47 EPS.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.64).

ACHV has been the subject of several other reports. UBS Group reissued a "buy" rating on shares of Achieve Life Sciences in a research report on Tuesday, June 23rd. Weiss Ratings upgraded shares of Achieve Life Sciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, May 22nd. Wall Street Zen raised shares of Achieve Life Sciences from a "sell" rating to a "hold" rating in a research report on Sunday, May 17th. Raymond James Financial initiated coverage on Achieve Life Sciences in a research note on Friday, June 26th. They set a "strong-buy" rating and a $20.00 price target for the company. Finally, Canaccord Genuity Group set a $13.00 price objective on Achieve Life Sciences and gave the stock a "buy" rating in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $16.00.

Achieve Life Sciences Stock Up 1.5%

Achieve Life Sciences stock opened at $6.77 on Wednesday. Achieve Life Sciences has a 1-year low of $2.37 and a 1-year high of $7.11. The firm has a market capitalization of $695.01 million, a price-to-earnings ratio of -6.04 and a beta of 2.24. The firm's fifty day moving average price is $6.00 and its two-hundred day moving average price is $4.89. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of 0.87.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ACHV. AQR Capital Management LLC purchased a new position in Achieve Life Sciences during the first quarter worth about $32,000. Magnolia Capital Advisors LLC purchased a new stake in Achieve Life Sciences in the 4th quarter valued at about $64,000. Jefferies Financial Group Inc. purchased a new stake in Achieve Life Sciences in the 4th quarter valued at about $84,000. HRT Financial LP bought a new position in shares of Achieve Life Sciences during the 4th quarter worth approximately $93,000. Finally, Robertson Stephens Wealth Management LLC lifted its position in shares of Achieve Life Sciences by 100.0% during the 4th quarter. Robertson Stephens Wealth Management LLC now owns 20,000 shares of the biopharmaceutical company's stock worth $99,000 after buying an additional 10,000 shares in the last quarter. 33.52% of the stock is owned by institutional investors.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc NASDAQ: ACHV is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source